by Barry | Sep 22, 2021 | Press Releases
Viewpoint advancing new, proprietary class of personalized 212 Pb-based alpha-particle radiopharmaceuticals to transform the treatment landscape of radiotherapies for cancerPositive preclinical data have demonstrated that a single dose of [212 Pb]VMT01 has...
by Barry | Sep 9, 2021 | Press Releases
VMT–NET Phase 1 imaging study to be followed by Phase 1/2a therapy study for the treatment of neuroendocrine tumors being conducted at the University of IowaPreclinical efficacy results demonstrated VMT–NET to significantly inhibit tumor growth and improve...
by Barry | Sep 8, 2021 | Press Releases
CORALVILLE, IA / September 8, 2021 / Viewpoint Molecular Targeting, Inc. (“Viewpoint” or the “Company”), a radiopharmaceutical company developing precision lead-212-based α-particle oncology therapeutics and complementary diagnostic...
by Barry | Jul 14, 2021 | Press Releases
Well-established research professional with expertise in early-stage pharmaceutical and biotechnology drug development Company driving advancement of proprietary image-guided alpha-particle radiotherapies designed to optimize treatment, improve efficacy, and minimize...
by Barry | Jul 7, 2021 | Press Releases
Companies forge relationship to accelerate peptide drug discovery for next-generation radiopharmaceuticals Pepscan brings proprietary world-leading peptide drug discovery expertise and technologies Viewpoint to apply expertise in radiopharmaceuticals, chelation...
by Barry | Jun 15, 2021 | Press Releases
– Presented data highlights the performance of Viewpoint’s chelation technology – Coralville, IA, June 15, 2021 – Viewpoint Molecular Targeting, Inc. (“Viewpoint” or the “Company”), a radiopharmaceutical company developing precision lead-212-based α-particle...
Recent Comments